20.49
Schrodinger Inc stock is traded at $20.49, with a volume of 668.60K.
It is down -0.34% in the last 24 hours and down -4.25% over the past month.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
See More
Previous Close:
$20.56
Open:
$20.38
24h Volume:
668.60K
Relative Volume:
0.54
Market Cap:
$1.92B
Revenue:
$193.35M
Net Income/Loss:
$-177.58M
P/E Ratio:
-8.3633
EPS:
-2.45
Net Cash Flow:
$-172.43M
1W Performance:
-2.66%
1M Performance:
-4.25%
6M Performance:
+0.94%
1Y Performance:
+9.87%
Schrodinger Inc Stock (SDGR) Company Profile
Name
Schrodinger Inc
Sector
Industry
Phone
503-299-1150
Address
1540 BROADWAY, NEW YORK, NY
Compare SDGR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SDGR
Schrodinger Inc
|
20.49 | 1.92B | 193.35M | -177.58M | -172.43M | -2.45 |
![]()
VEEV
Veeva Systems Inc
|
281.19 | 46.43B | 2.86B | 780.66M | 1.20B | 4.72 |
![]()
TEM
Tempus Ai Inc
|
68.34 | 12.01B | 803.32M | -709.10M | -212.68M | -7.8003 |
![]()
DOCS
Doximity Inc
|
60.41 | 10.79B | 550.17M | 201.35M | 232.07M | 1.00 |
![]()
HQY
Healthequity Inc
|
104.86 | 9.27B | 1.15B | 96.70M | -161.99M | 1.09 |
![]()
WAY
Waystar Holding Corp
|
39.27 | 7.03B | 906.14M | -52.62M | 89.62M | -0.3621 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-02-24 | Initiated | Leerink Partners | Outperform |
Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
May-05-23 | Resumed | Piper Sandler | Overweight |
Dec-19-22 | Initiated | Goldman | Neutral |
Mar-01-22 | Initiated | Citigroup | Buy |
Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Nov-19-21 | Initiated | Piper Sandler | Overweight |
Nov-11-21 | Downgrade | BofA Securities | Buy → Neutral |
Oct-13-21 | Initiated | Berenberg | Buy |
Sep-01-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
May-25-21 | Initiated | Craig Hallum | Buy |
Nov-23-20 | Upgrade | BofA Securities | Neutral → Buy |
Oct-12-20 | Upgrade | Jefferies | Hold → Buy |
Mar-02-20 | Initiated | BMO Capital Markets | Outperform |
Mar-02-20 | Initiated | Jefferies | Hold |
Mar-02-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Schrodinger Inc Stock (SDGR) Latest News
Schrodinger Announces Board Elections and Approvals - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger - Bluefield Daily Telegraph
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | SDGR Stock News - GuruFocus
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Where are the Opportunities in (SDGR) - news.stocktradersdaily.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, ... - Eagle-Tribune
Harbor Capital Advisors Inc. Grows Stake in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger slides after early-stage trial data for cancer therapy - MSN
Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results - Seeking Alpha
Schrödinger (SDGR) Shares Dip After Initial Phase 1 Trial Data - GuruFocus
Schrödinger Reports Encouraging Initial Phase 1 Clinical Data fo - GuruFocus
Schrodinger Reports 22% Response Rate in Phase 1 Trial of SGR-1505 for B-Cell Cancers; Shares Fall - MarketScreener
Schrödinger stock slides on cancer trial data (SDGR:NASDAQ) - Seeking Alpha
Transcript : Schrödinger, Inc.Special Call - MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc.SDGR - WV News
Schrodinger (SDGR) Reports Promising Phase 1 Results of SGR-1505 | SDGR Stock News - GuruFocus
Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress - Eagle-Tribune
Day 9 of Gains Streak for Schrodinger Stock with 24% Return (vs. 38% YTD) [6/11/2025] - Trefis
Schrodinger Inc (SDGR) Trading 5.17% Higher on Jun 11 - GuruFocus
California State Teachers Retirement System Reduces Holdings in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrödinger, Inc. (NASDAQ:SDGR) Receives Average Recommendation of “Buy” from Analysts - Defense World
Comparing Schrödinger (NASDAQ:SDGR) & Salarius Pharmaceuticals (NASDAQ:SLRX) - Defense World
Schrodinger Inc (SDGR) Trading 4.34% Higher on Jun 6 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Schrodinger Shows Rising Price Performance With Jump To 82 RS Rating - Investor's Business Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect - ACCESS Newswire
Kalkine NASDAQ 100 Top Stocks Leading Technology Giants Driving Market Growth - Kalkine Media
24,500 Shares in Schrödinger, Inc. (NASDAQ:SDGR) Acquired by Two Sigma Advisers LP - Defense World
Bank of America Corp DE Reduces Stock Position in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrodinger at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
Schrodinger at Jefferies Conference: Strategic Growth and Challenges - Investing.com Australia
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Two Sigma Investments LP Acquires New Stake in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Top 5 AI & Digital Biotech Companies (June 2025) - Securities.io
Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ProShare Advisors LLC Has $323,000 Stock Position in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Layoff Tracker: iTeos Winds Down Operations - BioSpace
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule - GuruFocus
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer - 01net
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer | SDGR Stock News - GuruFocus
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) To Newly Appointed Chief Commercial Officer - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to Connect - ACCESS Newswire
Schrodinger appoints Mannix Aklian as chief commercial officer - TipRanks
Schrödinger Appoints Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing - citybiz
Schrödinger Expands Executive Leadership Team with Appointment o - GuruFocus
Schrödinger Expands Executive Leadership Team With Appointment Of Mannix Aklian As Chief Commercial Officer - MarketScreener
Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing | SDGR Stock News - GuruFocus
Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing - Yahoo Finance
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $610,000 Stock Holdings in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
Schrodinger Inc Stock (SDGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Schrodinger Inc Stock (SDGR) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Akinsanya Karen | President of R&D, Therapeutics |
Apr 14 '25 |
Sale |
25.09 |
16,723 |
419,570 |
15,625 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):